Hawaii House Bill HB1108

Hawaii 2025 Regular Session

• Introduced: 1/23/25
• Refer: 1/23/25

Caption

Relating To Manufactured Hemp Products.

Summary

HB1108 clarifies Hawaii’s statutory definition of “manufactured hemp product” in chapter 328G, HRS. The bill amends the definition to expressly include not only certain processed hemp products intended for oral consumption or topical use, but also any other hemp products that the Department of Health may specify by rule under section 328G-4. The measure is framed as a technical correction to address ambiguity created by Act 263 (SLH 2023), which may have unintentionally narrowed the department’s authority to regulate new hemp product types. The bill also preserves the existing exclusions from the definition, making clear that living hemp plants, viable seeds, leaf materials, and floral materials are not manufactured hemp products. It takes effect upon approval and does not create a new regulatory program so much as confirm and restore the Department of Health’s ability to classify additional hemp products through rulemaking.

Impact

HB1108 would amend section 328G-1, Hawaii Revised Statutes, to broaden and clarify the scope of “manufactured hemp product” by tying it to Department of Health rules adopted under section 328G-4. In practical terms, this strengthens the department’s authority to regulate emerging hemp-derived products without needing a new statutory amendment each time a product category develops. The bill affects hemp producers, processors, retailers, and regulators by confirming that rule-based product classifications remain valid under state law.

Sentiment

The available context suggests the bill is generally technical and corrective in nature, with no recorded committee testimony or votes indicating opposition or controversy. Its stated purpose is to resolve an ambiguity in existing law rather than to change policy direction, which typically signals neutral to favorable legislative sentiment. The absence of recorded debate in the provided materials suggests the measure was likely treated as a housekeeping clarification.

Contention

The main point of potential contention is the scope of the Department of Health’s rulemaking authority. The bill responds to concern that the prior definition could be read to limit the department’s ability to regulate new hemp products as they emerge. Supporters would likely view the change as necessary to preserve flexible public-health oversight, while any critics might worry that the amendment gives the department too much discretion to expand regulation through rules rather than statute. No specific opposing arguments or named stakeholders appear in the provided record.